Key Points – AxoGen says its core strategy remains focused on developing the peripheral nerve repair market, and CEO Michael Dale reiterated confidence in the company’s Avance platform as a differentiated solution. – Recent reimbursement wins and the CMS outpatient rate increase…
ould help, but management said the financial impact is still hard to quantify because adoption and contracting take time; Aetna remains the last major payer pending a decision. – The company kept its double-digit growth outlook, expects gross margin to bottom in Q2 before improving, and plans to release second-half clinical data from a prostate nerve repair pilot that could inform a future go-to-market plan. AxoGen (NASDAQ:AXGN) President and CEO Michael Dale said the company’s growth strategy remains centered on developing the market for peripheral nerve repair, while recent reimbursement wins are expected to be positive but have not yet been quantified
Speaking during a company event, Dale said he was drawn to AxoGen because peripheral nerve function represents a “credible health condition” with a large underserved patient population and because the company’s Avance platform offers what he described as a differentiated solution relative to existing standards of care. “It’s a solution that based upon benefit versus risk as compared to existing options, is genuinely superior,” Dale said. Dale said AxoGen has gone through a traditional strategic planning process involving employees, the board, customers and investors. He emphasized that the company is operating from a single plan that has been discussed across those stakeholder groups.
Reimbursement Wins Seen as Positive, but Timing Remains Unclear Asked about recently announced reimbursement gains and their effect on revenue for the rest of 2026 and beyond, Dale said the company is still working to understand the magnitude and timing of the benefit. “We know it’s all gonna be good,” Dale said, while adding that the company has not yet…